Moleculin Biotech (MBRX) Short Interest Ratio & Short Volume → “This will be one of the biggest revolutions ever.” - NVIDIA CEO (From Behind the Markets) (Ad) Free MBRX Stock Alerts $4.77 +0.13 (+2.80%) (As of 05/31/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Moleculin Biotech Short Interest DataCurrent Short Interest34,200 sharesPrevious Short Interest31,100 sharesChange Vs. Previous Month+9.97%Dollar Volume Sold Short$168,264.00Short Interest Ratio0.9 Days to CoverLast Record DateMay 15, 2024Outstanding Shares2,310,000 sharesFloat Size2,230,000 sharesShort Percent of Float1.53%Today's Trading Volume3,875 sharesAverage Trading Volume23,876 sharesToday's Volume Vs. Average16% Short Selling Moleculin Biotech ? Sign up to receive the latest short interest report for Moleculin Biotech and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartMBRX Short Interest Over TimeMBRX Days to Cover Over TimeMBRX Percentage of Float Shorted Over Time Ad Behind the MarketsDon’t buy a single NVIDIA share before you see this...If you feel like NVIDIA is still a good buy - be careful. Billionaires like Steve Cohen, Stanley Druckenmiller and George Soros are ALL dumping NVIDIA... And piling into an overlooked sector...I've prepared a short briefing with all the proof Moleculin Biotech Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/202434,200 shares $168,264.00 +10.0%1.5%0.9 $4.92 4/30/202431,100 shares $156,122.00 +16.5%1.5%0.8 $5.02 4/15/202426,700 shares $119,082.00 -40.7%1.2%0.8 $4.46 3/31/202445,000 shares $265,950.00 +2,042.9%2.1%1.4 $5.91 3/15/20242,100 shares $15,576.75 -98.4%0.1%0.1 $7.42 2/29/2024134,400 shares $84,537.60 -2.4%N/A0.8 $0.63 Get the Latest News and Ratings for MBRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter. 2/15/2024137,700 shares $68,850.00 -37.4%N/A0.9 $0.50 1/31/2024220,000 shares $110,880.00 -8.5%N/A1.2 $0.50 1/15/2024240,300 shares $170,613.00 -23.8%N/A1.3 $0.71 12/31/2023315,300 shares $270,653.52 -7.5%N/A1.6 $0.86 12/15/2023340,800 shares $197,664.00 +35.3%N/A2.1 $0.58 11/30/2023251,900 shares $150,812.53 -15.2%N/A1.7 $0.60 11/15/2023296,900 shares $169,233.00 +59.7%N/A1.9 $0.57 10/31/2023185,900 shares $90,012.78 +131.8%N/A1.5 $0.48 10/15/202380,200 shares $36,090.00 -55.3%N/A0.7 $0.45 9/30/2023179,300 shares $76,650.75 +260.0%N/A1.2 $0.43 9/15/202349,800 shares $19,770.60 +30.7%N/A0.3 $0.40 8/31/202338,100 shares $21,336.00 -75.4%N/A0.2 $0.56 8/15/2023155,100 shares $94,455.90 +15.6%N/A1 $0.61 7/31/2023134,200 shares $84,975.44 +42.6%N/A0.7 $0.63 7/15/202394,100 shares $59,283.00 -20.8%N/A0.5 $0.63 6/30/2023118,800 shares $68,761.44 +611.4%N/A0.4 $0.58 6/15/202316,700 shares $9,853.00 +108.8%N/A0.1 $0.59 5/31/20238,000 shares $5,068.00 -59.4%N/A0 $0.63 5/15/202319,700 shares $12,139.14 +20.9%N/A0.1 $0.62 4/30/202316,300 shares $12,180.99 -30.3%0.1%0.1 $0.75 4/15/202323,400 shares $21,294.00 -14.6%0.1%0.1 $0.91 3/31/202327,400 shares $26,304.00 -26.3%0.1%0.4 $0.96 3/15/202337,200 shares $35,340.00 -13.9%0.1%0.5 $0.95 2/28/202343,200 shares $52,272.00 -30.1%0.2%0.5 $1.21 2/15/202361,800 shares $80,340.00 +56.9%0.2%0.7 $1.30 1/31/202339,400 shares $49,640.06 -49.0%0.1%0.4 $1.26 1/15/202377,200 shares $100,360.00 -34.9%0.3%0.8 $1.30 12/30/2022118,600 shares $125,716.00 +48.3%0.4%1.2 $1.06 12/15/202280,000 shares $110,400.00 -9.7%0.3%0.8 $1.38 11/30/202288,600 shares $127,584.00 +30.3%0.3%0.9 $1.44 11/15/202268,000 shares $64,593.20 +32.0%0.2%0.6 $0.95 10/31/202251,500 shares $51,500.00 -9.8%0.2%0.5 $1.00 10/15/202257,100 shares $57,100.00 -5.3%0.2%0.6 $1.00 9/30/202260,300 shares $63,918.00 -36.4%0.2%0.6 $1.06On June 10, Nvidia makes its next big move (Ad)A small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. We call them Nvidia’s “Silent Partners.”Click here to find out who they are. 9/15/202294,800 shares $134,616.00 -40.0%0.3%1 $1.42 8/31/2022158,100 shares $233,988.00 +59.2%0.6%2 $1.48 8/15/202299,300 shares $178,740.00 +85.6%0.4%2 $1.80 7/31/202253,500 shares $90,415.00 -54.7%0.2%1 $1.69 7/15/2022118,200 shares $195,467.34 +25.5%0.4%2 $1.65 6/30/202294,200 shares $136,590.00 -37.9%0.3%1.4 $1.45 6/15/2022151,600 shares $210,724.00 -39.0%0.5%1.9 $1.39 5/31/2022248,500 shares $372,750.00 +31.0%0.9%2.9 $1.50 5/15/2022189,700 shares $235,228.00 -37.0%0.7%1.9 $1.24 4/30/2022301,000 shares $478,590.00 -28.0%1.1%2.8 $1.59 4/15/2022418,300 shares $836,600.00 +0.6%1.5%3.5 $2.00 3/31/2022415,900 shares $740,302.00 -4.7%1.5%3.4 $1.78 3/15/2022436,400 shares $554,228.00 -9.6%1.6%2.4 $1.27 2/28/2022482,500 shares $670,675.00 +9.2%1.8%2.4 $1.39 2/15/2022441,900 shares $645,174.00 -9.9%1.7%1.8 $1.46 1/31/2022490,200 shares $740,202.00 -7.8%1.8%1.9 $1.51 1/15/2022531,600 shares $909,036.00 +2.0%2.0%1.9 $1.71 12/31/2021521,100 shares $969,246.00 -11.0%1.9%1.8 $1.86 12/15/2021585,400 shares $1.22 million +2.2%2.2%2.3 $2.08 11/30/2021572,600 shares $1.19 million -8.7%2.1%2.4 $2.07 11/15/2021626,800 shares $1.49 million -3.3%2.3%3.2 $2.38 10/29/2021648,000 shares $1.71 million -6.1%2.4%3.5 $2.64 10/15/2021690,400 shares $1.87 million +3.6%2.6%4 $2.71 9/30/2021666,700 shares $2.00 million -6.3%2.5%3.8 $3.00 9/15/2021711,400 shares $2.07 million -5.6%2.7%3.7 $2.91 8/31/2021753,900 shares $2.32 million +5.4%2.8%3.5 $3.08 8/13/2021715,200 shares $2.12 million -7.3%2.7%2.9 $2.97 7/30/2021771,800 shares $2.41 million -18.8%2.9%2.9 $3.12 7/15/2021949,900 shares $3.25 million -1.0%3.6%3.3 $3.42 6/30/2021959,300 shares $3.52 million +17.8%3.6%1.7 $3.67 6/15/2021814,600 shares $3.08 million -13.8%3.1%0.7 $3.78 5/28/2021944,700 shares $3.50 million -14.9%3.5%0.8 $3.70 5/14/20211,110,000 shares $3.63 million -4.3%4.2%0.9 $3.27 4/30/20211,160,000 shares $4.21 million +26.7%4.4%0.7 $3.63 4/15/2021915,500 shares $3.38 million +78.0%3.4%0.3 $3.69 3/31/2021514,200 shares $2.19 million +70.9%1.9%0.2 $4.25 3/15/2021300,800 shares $1.34 million -50.1%1.1%0.1 $4.44 2/26/2021602,500 shares $2.62 million +44.7%2.6%0.3 $4.35 2/12/2021416,500 shares $2.23 million -84.9%1.8%0.2 $5.36 1/29/20212,760,000 shares $16.06 million +8.2%12.6%1.4 $5.82 1/15/20212,550,000 shares $15.45 million +4.9%N/A1 $6.06 12/31/20202,430,000 shares $12.17 million +4.7%N/A1.2 $5.01 12/15/20202,320,000 shares $10.75 million -0.4%N/A1.6 $4.63 11/30/20202,330,000 shares $10.82 million -7.2%N/A1.7 $4.64 11/15/20202,510,000 shares $11.58 million -3.5%N/A5 $4.61 10/30/20202,600,000 shares $11.23 million -11.3%N/A4.9 $4.32 10/15/20202,930,000 shares $14.29 million -5.5%N/A4.1 $4.88 9/30/20203,100,000 shares $15.12 million +2.0%N/A1 $4.88 9/15/20203,040,000 shares $14.85 million -10.3%N/A1 $4.88 8/31/20203,390,000 shares $17.83 million -7.6%N/A1.1 $5.26On June 10, Nvidia makes its next big move (Ad)A small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. We call them Nvidia’s “Silent Partners.”Click here to find out who they are. 8/14/20203,670,000 shares $21.58 million -5.4%N/A1.1 $5.88 7/31/20203,880,000 shares $26.77 million +19.0%N/A1.2 $6.90 7/15/20203,260,000 shares $20.93 million -11.7%N/A1 $6.42 6/30/20203,690,000 shares $21.43 million -13.2%N/A0.7 $5.81 6/15/20204,250,000 shares $28.56 million -3.2%N/A0.8 $6.72 5/29/20204,390,000 shares $28.71 million +8.7%N/A0.7 $6.54 5/15/20204,040,000 shares $25.94 million -28.2%N/A0.7 $6.42 4/30/20205,630,000 shares $36.82 million +10.8%N/A1 $6.54 4/15/20205,080,000 shares $38.40 million +213.6%N/A0.9 $7.56 3/31/20201,620,000 shares $1.85 million +202.9%N/A0.4 $1.14 3/13/2020534,900 shares $604,437.00 -27.4%1.4%1.5 $1.13 2/28/2020736,300 shares $404,965.00 -35.4%1.9%1.1 $0.55 2/14/20201,140,000 shares $649,800.00 -16.8%2.9%1.8 $0.57 1/31/20201,370,000 shares $945,300.00 -4.2%3.5%2.5 $0.69 1/15/20201,430,000 shares $1.07 million -20.1%3.7%6.1 $0.75 12/31/20191,790,000 shares $1.68 million -6.3%4.6%7.8 $0.94 MBRX Short Interest - Frequently Asked Questions What is Moleculin Biotech's current short interest? Short interest is the volume of Moleculin Biotech shares that have been sold short but have not yet been closed out or covered. As of May 15th, investors have sold 34,200 shares of MBRX short. 1.53% of Moleculin Biotech's shares are currently sold short. Learn More on Moleculin Biotech's current short interest. What is a good short interest ratio for Moleculin Biotech? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. MBRX shares currently have a short interest ratio of 1.0. Learn More on Moleculin Biotech's short interest ratio. What is a good short interest percentage for Moleculin Biotech? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.53% of Moleculin Biotech's floating shares are currently sold short. Is Moleculin Biotech's short interest increasing or decreasing? Moleculin Biotech saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 34,200 shares, an increase of 10.0% from the previous total of 31,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Moleculin Biotech's float size? Moleculin Biotech currently has issued a total of 2,310,000 shares. Some of Moleculin Biotech's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Moleculin Biotech currently has a public float of 2,230,000 shares. How does Moleculin Biotech's short interest compare to its competitors? 1.53% of Moleculin Biotech's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Moleculin Biotech: NextCure, Inc. (0.43%), HCW Biologics Inc. (0.01%), Daré Bioscience, Inc. (0.53%), NRx Pharmaceuticals, Inc. (7.00%), Acurx Pharmaceuticals, Inc. (4.43%), Reviva Pharmaceuticals Holdings, Inc. (6.38%), DURECT Co. (3.13%), VYNE Therapeutics Inc. (0.46%), Eyenovia, Inc. (10.27%), Cara Therapeutics, Inc. (5.23%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Moleculin Biotech stock? Short selling MBRX is an investing strategy that aims to generate trading profit from Moleculin Biotech as its price is falling. MBRX shares are trading up $0.13 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Moleculin Biotech? A short squeeze for Moleculin Biotech occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of MBRX, which in turn drives the price of the stock up even further. How often is Moleculin Biotech's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MBRX, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: NextCure Short Squeeze HCW Biologics Short Squeeze Daré Bioscience Short Squeeze NRx Pharmaceuticals Short Squeeze Acurx Pharmaceuticals Short Squeeze Reviva Pharmaceuticals Short Squeeze DURECT Short Squeeze VYNE Therapeutics Short Squeeze Eyenovia Short Squeeze Cara Therapeutics Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:MBRX) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.